MDxHealth SA (MDXH) AI Stock Analysis

MDxHealth SA operates as a precision diagnostics company providing commercial-stage urologic solutions across the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and other international markets. The company specializes in innovative genomic testing solutions for prostate cancer, highlighted by SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic test. These diagnostic tools aim to assist physicians in identifying prostate cancer with high accuracy while reducing the need for invasive procedures. Established in 2003 and headquartered in Herstal, Belgium, the company was formerly known as OncoMethylome Sciences SA before rebranding in October 2010.

MDxHealth grew revenue from $22.2M in FY2021 to $107.9M in FY2025, delivering a 5-year revenue CAGR of 42.3% through FY2025. Annual top-line growth moderated from 89.4% in FY2023 to 28.3% in FY2024 and 19.8% in FY2025. Gross margin improved from 47.5% in FY2021 to 59.7% in FY2025, after reaching 62.6% in FY2023. Operating margins remained negative across all reported years, progressing from -120.7% in FY2021 to -14.3% in FY2025. Net losses were -$29.0M in FY2021, -$44.0M in FY2022, -$43.1M in FY2023, -$38.1M in FY2024, and -$33.5M in FY2025. For the trailing twelve months ended June 30, 2026, revenue was $114.0M with a profit margin of -32.7%, and quarterly revenue increased 2.3% year-over-year.

As of June 30, 2026, MDxHealth held $19.2M in cash and short-term investments against $105.8M in total debt, resulting in net debt of $86.6M. Total assets stood at $132.1M, and the current ratio was 1.15. The company reported negative shareholders' equity of -$30.4M. Cash flow from operations was -$10.4M in FY2025, and free cash flow was -$11.6M, alongside capital expenditures of $1.2M. Over five years, the company's share count increased 329.9%.

MDxHealth has a market cap of $19.7M and an enterprise value of $143.9M. The stock trades at a price-to-sales multiple of 0.2x, below the 4.1x median of its US-listed Healthcare peers. Its enterprise value-to-revenue is 1.3x. MDxHealth trades at a forward P/E of 27.7x, compared to the peer median forward P/E of 17.3x, and an EV/EBITDA of 17.6x versus the peer median of 12.0x. Price-to-book is 23.6x. Over the past year, MDXH declined 94.9%, while the S&P 500 (SPY) returned 16.8%.

Wall Street coverage includes 4 Strong Buy and 2 Hold ratings. The mean price target is $1.12, representing 443.5% above the last close of $0.21 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $97.1M and an EPS of -$0.46. For the next fiscal year, consensus estimates forecast revenue of $109.9M and an EPS of -$0.38 from 1 analyst. MDxHealth posted 0 EPS beats over the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of MDxHealth SA (MDXH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MDXH income statement, MDXH balance sheet, MDXH key metrics, MDXH analyst forecast, MDXH chart. See the MDXH stock overview for the latest quote and news.